Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cannabidiol in Refractory Epileptic Crisis in Children and Adolescents
NCT02783092Phase 3Unknown
- Start
- Jan 2019
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in epilepsy comparing Cannabidiol with Placebo (2 arms). Primary endpoints: Rate of responsive patients at 17 weeks and Frequency of epileptic seizures at 17 weeks. Status: unknown.
02
Drugs
cannabidiol
03
Conditions
epilepsy
Beyond the preview
Go deeper on NCT02783092.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02783092.